Liu X, Wang G, Chen Y, Ma S, Huang B, Song S
BMC Public Health. 2025; 25(1):945.
PMID: 40065230
PMC: 11895191.
DOI: 10.1186/s12889-025-21979-y.
Chen C, Saha E, Fischer J, Ben Guebila M, Fanfani V, Shutta K
bioRxiv. 2025; .
PMID: 39975108
PMC: 11838606.
DOI: 10.1101/2025.02.03.636354.
Esendagli D, Mastromarino M, Valverde Zuniga A, Migliore M, Meloni F
ERJ Open Res. 2025; 11(1).
PMID: 39872383
PMC: 11770695.
DOI: 10.1183/23120541.01046-2024.
Altaf M, Zahra H, Majied H, Niazi I, Farooq H
Cureus. 2024; 16(11):e74572.
PMID: 39735116
PMC: 11680465.
DOI: 10.7759/cureus.74572.
Tang H, Voon F, Sim E
Cancer Rep (Hoboken). 2024; 7(12):e70095.
PMID: 39725665
PMC: 11671240.
DOI: 10.1002/cnr2.70095.
Incidence, prevalence, and survival of lung cancer in the United Kingdom from 2000-2021: a population-based cohort study.
Corby G, Barclay N, Tan E, Burn E, Delmestri A, Duarte-Salles T
Transl Lung Cancer Res. 2024; 13(9):2187-2201.
PMID: 39430337
PMC: 11484731.
DOI: 10.21037/tlcr-24-241.
Sex-Based Differences in Lung Cancer Incidence: A Retrospective Analysis of Two Large US-Based Cancer Databases.
Ratnakaram K, Yendamuri S, Groman A, Kalvapudi S
Cancers (Basel). 2024; 16(19).
PMID: 39409866
PMC: 11476236.
DOI: 10.3390/cancers16193244.
Exploring Genetic Variants and Platinum Chemotherapy Response in Indonesian Non-Small Cell Lung Cancer Patients: Insights from rs13181.
Afifah N, Permatasari L, Diantini A, Intania R, Wijaya I, Obinata H
Onco Targets Ther. 2024; 17:767-776.
PMID: 39319218
PMC: 11421434.
DOI: 10.2147/OTT.S475219.
Global burden of lung cancer in 2022 and projected burden in 2050.
Guo L, Zhu C, Cai L, Zhang X, Fang Y, Chen H
Chin Med J (Engl). 2024; 137(21):2577-2582.
PMID: 39313774
PMC: 11557091.
DOI: 10.1097/CM9.0000000000003268.
Sex Difference in Disease-Related Adverse Events Post-Diagnosis of Lung Cancer Brain Metastases in Medicare Individuals ≥ 66 Years of Age.
Dmukauskas M, Cioffi G, Waite K, Mammoser A, Sloan A, Ma P
Cancers (Basel). 2024; 16(17).
PMID: 39272844
PMC: 11394199.
DOI: 10.3390/cancers16172986.
Unusual presentation of rearranged metastatic non-small cell lung cancer.
Chen L, Keating C, Leb J, Saqi A, Shu C
Respir Med Case Rep. 2024; 51:102091.
PMID: 39257471
PMC: 11386496.
DOI: 10.1016/j.rmcr.2024.102091.
Investigating sex, race, and geographic disparities in bronchus and lung cancer mortality in the United States: a comprehensive longitudinal study (1999-2020) utilizing CDC WONDER data.
Rahman H, Ali Fahim M, Salman A, Kumar S, Raja A, Raja S
Ann Med Surg (Lond). 2024; 86(9):5361-5369.
PMID: 39238989
PMC: 11374286.
DOI: 10.1097/MS9.0000000000002387.
Detection of cancer-associated cachexia in lung cancer patients using whole-body [F]FDG-PET/CT imaging: A multi-centre study.
Ferrara D, Abenavoli E, Beyer T, Gruenert S, Hacker M, Hesse S
J Cachexia Sarcopenia Muscle. 2024; 15(6):2375-2386.
PMID: 39189415
PMC: 11634466.
DOI: 10.1002/jcsm.13571.
Natural Compounds for Preventing Age-Related Diseases and Cancers.
Ki M, Youn S, Kim D, Pack S
Int J Mol Sci. 2024; 25(14).
PMID: 39062777
PMC: 11276798.
DOI: 10.3390/ijms25147530.
Real-world comprehensive genomic and immune profiling reveals distinct age- and sex-based genomic and immune landscapes in tumors of patients with non-small cell lung cancer.
Wallen Z, Ko H, Nesline M, Hastings S, Strickland K, Previs R
Front Immunol. 2024; 15:1413956.
PMID: 38975340
PMC: 11224431.
DOI: 10.3389/fimmu.2024.1413956.
The Triterpenoid CDDO-Methyl Ester Reduces Tumor Burden, Reprograms the Immune Microenvironment, and Protects from Chemotherapy-Induced Toxicity in a Preclinical Mouse Model of Established Lung Cancer.
Moerland J, Liby K
Antioxidants (Basel). 2024; 13(6).
PMID: 38929060
PMC: 11201246.
DOI: 10.3390/antiox13060621.
Antiproliferative effect of indeno[1,2-d]thiazolo[3,2-a]pyrimidine analogues on IL-6 mediated STAT3 and role of the apoptotic pathway in albino Wistar rats of ethyl carbamate-induced lung carcinoma: In-silico, In-vitro, and In-vivo study.
Sonkar A, Verma A, Yadav S, Kumar R, Singh J, Keshari A
Cancer Cell Int. 2024; 24(1):219.
PMID: 38926695
PMC: 11201866.
DOI: 10.1186/s12935-024-03390-6.
mutation testing, treatment and survival in stage I-III non-small cell lung cancer: CancerLinQ Discovery database retrospective analysis.
Muthusamy B, Berktas M, Li J, Thomas D, Sun P, Taylor A
Future Oncol. 2024; 20(28):2083-2096.
PMID: 38916211
PMC: 11497985.
DOI: 10.1080/14796694.2024.2347826.
Lung cancer in females-sex-based differences from males in epidemiology, biology, and outcomes: a narrative review.
Gee K, Yendamuri S
Transl Lung Cancer Res. 2024; 13(1):163-178.
PMID: 38405003
PMC: 10891406.
DOI: 10.21037/tlcr-23-744.
Cell-Free DNA 5-Hydroxymethylcytosine Signatures for Lung Cancer Prognosis.
Shao J, Olsen R, Kasparian S, He C, Bernicker E, Li Z
Cells. 2024; 13(4.
PMID: 38391911
PMC: 10886903.
DOI: 10.3390/cells13040298.